Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICARUS-BREAST01 patritumab deruxtecan in HER3-high HR-positive advanced breast cancer
2020-005722-28Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patritumab deruxtecan in breast cancer, sponsored by Gustave Roussy. Primary endpoint: Confirmed objective response rate. Started Jan 2021; status: active.
02
Drugs
patritumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-005722-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005722-28.